Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
Dae Sik Kim, Yoo Jin Na, Myoung Hee Kang, Soo-Young Yoon, Chul Won Choi
Korean J Intern Med. 2016;31(2):357-366. Published online February 15, 2016
Background/Aims: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed, and a substantial number of patients need alternative treatment ..
|